-3.5 | | SAP30L-AS1 | 'P0 cells' vs 'untreated P4 cells' | passage, treatment | Transcription profiling by high throughput sequencing of human fetal differentiated P0 retinal pigment epithelial cells, mesenchymal P4 cells, and A-83-01 rescued P4 cells |
3 | | SAP30L-AS1 | 'HER2 Positive Breast Carcinoma; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
2.8 | | SAP30L-AS1 | 'tumor necrosis factor alpha' vs 'none' in 'brain microvascular endothelial cell; co-culture' | cell type, growth condition, stimulus | Reactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin |
-2.6 | | SAP30L-AS1 | 'KLF17 overexpression' vs 'wild type' at '5 day' | phenotype, time | RNA-seq of hESCs undergoing primed to naive-like resetting via exogenous KLF17 overexpression |
-2.6 | | SAP30L-AS1 | 'colorectal carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.5 | | SAP30L-AS1 | 'SENCR_knockdown' vs 'normal' | genotype | Identification and Initial Functional Characterization of SENCR, a Long Non-Coding RNA Enriched in Human Vascular Cells |
-2.4 | | SAP30L-AS1 | 'SENCR_control' vs 'normal' | genotype | Identification and Initial Functional Characterization of SENCR, a Long Non-Coding RNA Enriched in Human Vascular Cells |
-2.4 | | SAP30L-AS1 | 'sebaceous of Jadassohn nevus' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
-2.4 | | SAP30L-AS1 | 'actinic keratosis' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
2.3 | | SAP30L-AS1 | 'tumor necrosis factor alpha' vs 'none' in 'brain microvascular endothelial cell; monoculture' | cell type, growth condition, stimulus | Reactive astrocytes transduce blood-brain barrier inflammation through a TNFα-STAT3 signaling axis and secretion of alpha 1-antichymotrypsin |
-2.2 | | SAP30L-AS1 | 'hepatobiliary carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2.1 | | SAP30L-AS1 | 'squamous cell carcinoma' vs 'normal' | block, disease | RNA-seq of a panel of non-melanoma skin cancer lesions |
2.1 | | SAP30L-AS1 | 'non-triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
-2 | | SAP30L-AS1 | 'breast carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
2 | | SAP30L-AS1 | 'poly(I:C); 25 microgram per milliliter' vs 'none' in 'none; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-2 | | SAP30L-AS1 | 'glioblastoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
-2 | | SAP30L-AS1 | 'pancreatic adenocarcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
2 | | SAP30L-AS1 | 'triple-negative breast cancer; breast carcinoma' vs 'normal' | clinical information, disease | RNA-seq of 17 breast tumor samples of three different subtypes and normal human breast organoids samples |
-2 | | SAP30L-AS1 | 'doxycycline; 0.5 microgram per milliliter; Day 4 post Neurogenin induction' vs 'control' | compound, treatment | Rapid neurogenesis through transcriptional activation in human stem cell (RNA-Seq) |
-1.9 | | SAP30L-AS1 | 'MEF2D-HNFNPUL1 knockdown by siRNA' vs 'luciferase siRNA' | RNA interference | RNA-seq for gene expression changes upon silencing MEF2D-fusion in a MEF2D-HNRNPUL1 fusion-expressing Kasumi-7 cell line |
1.9 | | SAP30L-AS1 | 'neoplasm' vs 'normal tissue adjacent to neoplasm' | sampling site | Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma |
1.9 | | SAP30L-AS1 | 'JQ1 (1 micromolar) and THZ1 (35 nanomolar)' vs 'none' | compound | RNA-seq of IMR-5/75 neuroblastoma cell line treated with JQ1, THZ1 or combination against untreated controls |
1.9 | | SAP30L-AS1 | ' neural stem cell' vs 'induced pluripotent stem cell' in 'normal' | cell type, disease | Human iPSC-Derived Cerebellar Neurons from a Patient with Ataxia-Telangiectasia Reveal Disrupted Gene Regulatory Networks |
-1.9 | | SAP30L-AS1 | '3 h DRB 8 min 4sU' vs 'untreated' | treatment | 4sUDRB-seq: measuring transcription elongation and initiation genomewide |
1.8 | | SAP30L-AS1 | 'valproic acid; 15 millimolar' vs 'control' at '1 day' | compound, sampling time point | RNA-seq of Primary Human Hepatocytes (PHH) exposed to Valproic Acid (VPA) for 3 days daily and 3 days daily exposure followed by 3 days washout. |
1.8 | | SAP30L-AS1 | 'young cells' vs 'spontaneously immortal cells; control' | phenotype, treatment | Pathway Profiling of Replicative and Induced Senescence |
-1.7 | | SAP30L-AS1 | 'induced pluripotent stem cell' vs 'fibroblast of dermis' in 'Klinefelter's syndrome' | cell type, disease | Klinefelter syndrome derived hiPSCs show similar XCI behavior as female hPSCs |
-1.7 | | SAP30L-AS1 | '3 h DRB 0 min 4sU' vs 'untreated' | treatment | 4sUDRB-seq: measuring transcription elongation and initiation genomewide |
1.6 | | SAP30L-AS1 | 'contrast-enhancing core; glioma' vs 'normal' | biopsy site, disease | Transcription profiling by high throughput sequencing in the margins of glioblastoma |
1.6 | | SAP30L-AS1 | 'esophageal adenocarcinoma' vs 'normal' | disease, disease staging | Whole transcriptome profiling of Esophageal adenocarcinoma and Barrett's |
-1.6 | | SAP30L-AS1 | 'EIF2AK3 homozygous knockout' vs 'wild type' | phenotype | RNA-seq of human near-haploid cell line HAP1 with CRISPR-edited frameshift mutations |
-1.5 | | SAP30L-AS1 | 'non-small cell lung carcinoma' vs 'normal' | block, disease | RNA-seq of blood platelets from six tumor types and healthy donors |
1.5 | | SAP30L-AS1 | 'ssON; 0.5 micromolar' vs 'none' in 'none; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
-1.5 | | SAP30L-AS1 | 'myxosarcoma' vs 'normal' | disease | Atrial Myxomas Arise From Multipotent Myxoid Cardiac Stem Cells |
1.5 | | SAP30L-AS1 | 'late passage' vs 'early passage' | phenotype | Transcription profiling by high throughput sequencing in late (P13) and early P(4) passage cells |
1.4 | | SAP30L-AS1 | 'progenitor cell of endocrine pancreas' vs 'definitive endoderm cell' in 'GATA6 R456C/+; Patient A" | cell line, cell type, genotype, individual | RNA-seq of definitive endoderm and pancreatic progenitor cells derived in vitro from human pluripotent stem cells in order to study the role of transcription factor GATA6 in human pancreas development |
1.4 | | SAP30L-AS1 | 'poly I:C' vs 'mock' in 'ncgRNA' | genotype, stimulus | Effects of innate immune stimuli on PAF1 knockout cells |
1.3 | | SAP30L-AS1 | 'THZ1 (35 nanomolar)' vs 'none' | compound | RNA-seq of IMR-5/75 neuroblastoma cell line treated with JQ1, THZ1 or combination against untreated controls |
1.3 | | SAP30L-AS1 | 'autism' vs 'normal' | disease | Transcriptomic analysis of autistic brain reveals convergent molecular pathology [high-throughput sequence data] |
1.2 | | SAP30L-AS1 | 'PAX2 siRNA' vs 'control' | RNA interference | Transcription profiling by high throughput sequencing of control- and PAX2-siRNA-transfected human epididymis epithelial cells |
-1.2 | | SAP30L-AS1 | 'Influenza A virus (A/California/07-00001/2009(H1N1))' vs 'none' in 'poly(I:C); 25 microgram per milliliter; none' | compound, infect, stimulus | RNA-seq of H1N1 infected monocyte-derived dendritic cells (MoDC), stimulated with single-stranded oligonucleotides (ssON) and/or Poly I:C. |
1.2 | | SAP30L-AS1 | 'hypoxia' vs 'normoxia' in 'MDAMB468; Plasmax media' | cell line, environmental stress, growth condition | RNA-seq of human breast cancer cell lines: CAL120; MDAMB468 and BT549 incubated in DMEM-F12 and Plasmax in normoxia (21%O2) and hypoxia (0.1% O2) |
-1.2 | | SAP30L-AS1 | 'EGR2-E356K' vs 'wild type genotype' | genotype | RNA-sequencing of human B cells to investigate chronic lymphocytic leukemia mutations observed in hematopoietic multipotent progenitor fractions |
1.1 | | SAP30L-AS1 | 'tumor tissue' vs 'adjacent non-tumor tissue' | sampling site | RNA-seq of prostate cancer and adjacent normal tissues from 14 patients |
-1.1 | | SAP30L-AS1 | '6 hour' vs '0 hour' in 'MCF-10A' | cell line, time | Knock-in of PIK3CA-H1047R into MCF-10A |
1 | | SAP30L-AS1 | 'wild type ZFP36L1; 4-hydroxytamoxifen; senescent cell' vs 'wild type non-senescent cell' | compound, genotype, phenotype | Analysis of the senescent transcriptome upon expression of a ZFP36L1 phosphomutant |
1 | | SAP30L-AS1 | 'GATA6 c.611_614delACCT/c.611_614delACCT' vs 'wild type genotype' in 'H9; definitive endoderm cell' | cell line, cell type, genotype, individual | RNA-seq of definitive endoderm and pancreatic progenitor cells derived in vitro from human pluripotent stem cells in order to study the role of transcription factor GATA6 in human pancreas development |
1 | | SAP30L-AS1 | 'Barrett’s esophagus; non-dysplastic' vs 'normal' | disease, disease staging | Whole transcriptome profiling of Esophageal adenocarcinoma and Barrett's |
1 | | SAP30L-AS1 | 'SQLE knockdown by shRNA' vs 'control shRNA' | RNA interference | Endothelial cell heterogeneity in pathological angiogenesis characterized by metabolic transcriptome diversity |
1 | | SAP30L-AS1 | 'JQ1 (1 micromolar)' vs 'none' | compound | RNA-seq of IMR-5/75 neuroblastoma cell line treated with JQ1, THZ1 or combination against untreated controls |
